- Home
- CCEC vs ATAI Comparison
CCEC vs ATAI Comparison
Compare CCEC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$20.78
HOLD
Current Price
$3.97
Company Overview
Basic Information| Metric | CCEC | ATAI |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCEC | ATAI |
|---|---|---|
| Price | $20.78 | $3.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $25.50 | $13.86 |
| AVG Volume (30 Days) | 4.9K | ★ 3.8M |
| Earning Date | 02-06-2026 | 03-16-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 304.00 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | ★ $421,795,000.00 | $3,018,000.00 |
| Revenue This Year | $14.29 | $956.49 |
| Revenue Next Year | $12.32 | N/A |
| P/E Ratio | $4.28 | ★ N/A |
| Revenue Growth | 32.74 | ★ 811.78 |
| 52 Week Low | $14.09 | $1.15 |
| 52 Week High | $24.83 | $6.75 |
Technical Indicators
Market Signals| Indicator | CCEC | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 53.26 |
| Support Level | $20.21 | $3.32 |
| Resistance Level | $22.58 | $4.01 |
| Average True Range (ATR) | 0.52 | 0.24 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 23.84 | 75.89 |
Price Performance
Historical Comparison CCEC
ATAI
About CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.